ROLE OF ALPHA BLOCKER IN URETERORENOSCOPY.

PAFMJ Pub Date : 2021-12-30 DOI:10.51253/pafmj.v6i6.5647
A. Nadeem, Noreen Anwar, N. Ahmed, Yasser Saeed Khan, Irum Rashid, M. Ali
{"title":"ROLE OF ALPHA BLOCKER IN URETERORENOSCOPY.","authors":"A. Nadeem, Noreen Anwar, N. Ahmed, Yasser Saeed Khan, Irum Rashid, M. Ali","doi":"10.51253/pafmj.v6i6.5647","DOIUrl":null,"url":null,"abstract":"Objective: To determine the efficacy of alpha blockers in successful management of lower and mid ureteral stones by ureterorenoscopy. \nStudy Design: Comparative prospective study. \nPlace and Duration of Study: Department of Urology, Combined Military Hospital Quetta Pakistan, from Jul 2018 to Dec 2019. \nMethodology: Total of 150 patients having mid and lower ureteric calculi requiring ureterorenoscopy were divided into two groups. Group A included patients without pre-treatment with alpha blocker was administered before they were subjected to ureterorenoscopy. Study group B included patients who received daily oral dose of alpha blocker, Tamsulosin 0.4 mg twice daily, for 1 week before ureterorenoscopy. Per-operative findings in both the groups were recorded. Results were analyzed by comparing the outcome between both groups in terms of ease of performing procedure, duration of procedure, complications, duration of hospital stay and need for stent placement. \nResults: Mean operative time was significantly shorter in group B as compared to group A, (15.9 ± 3.81 min vs. 21.9 ± 3.63 min; p≤0.001). Demographic and stone characteristics were comparable between the both groups. Success rate was 74 (98.7%), in group B as compared to 68 (90.7%) in group A, with statistically significant difference (p=0.020). Complications in group B were less frequent 1 (1.3%) vs 7 (9.3%) in group A (p-value=0.027). \nConclusion: Use of alpha blockers for one week before performing ureterorenoscopy resulted in fewer complications and made the procedure easier to perform as well.","PeriodicalId":19982,"journal":{"name":"PAFMJ","volume":"18 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PAFMJ","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.51253/pafmj.v6i6.5647","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To determine the efficacy of alpha blockers in successful management of lower and mid ureteral stones by ureterorenoscopy. Study Design: Comparative prospective study. Place and Duration of Study: Department of Urology, Combined Military Hospital Quetta Pakistan, from Jul 2018 to Dec 2019. Methodology: Total of 150 patients having mid and lower ureteric calculi requiring ureterorenoscopy were divided into two groups. Group A included patients without pre-treatment with alpha blocker was administered before they were subjected to ureterorenoscopy. Study group B included patients who received daily oral dose of alpha blocker, Tamsulosin 0.4 mg twice daily, for 1 week before ureterorenoscopy. Per-operative findings in both the groups were recorded. Results were analyzed by comparing the outcome between both groups in terms of ease of performing procedure, duration of procedure, complications, duration of hospital stay and need for stent placement. Results: Mean operative time was significantly shorter in group B as compared to group A, (15.9 ± 3.81 min vs. 21.9 ± 3.63 min; p≤0.001). Demographic and stone characteristics were comparable between the both groups. Success rate was 74 (98.7%), in group B as compared to 68 (90.7%) in group A, with statistically significant difference (p=0.020). Complications in group B were less frequent 1 (1.3%) vs 7 (9.3%) in group A (p-value=0.027). Conclusion: Use of alpha blockers for one week before performing ureterorenoscopy resulted in fewer complications and made the procedure easier to perform as well.
阻滞剂在输尿管镜检查中的作用。
目的:探讨α受体阻滞剂在输尿管镜下成功治疗输尿管中下部结石的疗效。研究设计:比较前瞻性研究。学习地点和时间:2018年7月至2019年12月,巴基斯坦奎达联合军队医院泌尿外科。方法:将150例输尿管中下段结石需要输尿管镜检查的患者分为两组。A组患者在接受输尿管镜检查前未进行α受体阻滞剂预处理。研究B组患者在输尿管镜检查前接受每日口服剂量的α受体阻滞剂坦索罗辛0.4 mg,每日两次,持续1周。记录两组患者术中表现。比较两组患者在手术难易程度、手术时间、并发症、住院时间和支架放置需求等方面的结果。结果:B组平均手术时间明显短于A组(15.9±3.81 min vs 21.9±3.63 min);p≤0.001)。两组之间的人口统计学和结石特征具有可比性。B组治疗成功率为74例(98.7%),A组为68例(90.7%),差异有统计学意义(p=0.020)。B组并发症发生率为1例(1.3%),A组为7例(9.3%)(p值=0.027)。结论:输尿管镜检查前使用α受体阻滞剂一周,并发症少,操作方便。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信